Simulation in Clinical Drug Development

Biosimulation in Drug Development

Volumn , Issue , 2008, Pages 1-26

  Perez Ruixo, Juan Jose ^a   De Ridder, Filip ^a   Kimko, Hui ^b   Samtani, Mahesh ^b   Cox, Eugene ^c   Mohanty, Surya ^b   Vermeulen, An ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c JOHNSON AND JOHNSON   (United States)

Author keywords

Biosimulation; Drug development; Phase I studies; Phase II studies; Phase III

Indexed keywords

EID: 84889297594     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527622672.ch1     Document Type: Chapter

References (49)

1. U.S. Food and Drug Administration: Innovation/stagnation. Challenge and opportunity on the critical path to new medical products. View from the U.S. Food and Drug Administration (FDA). U.S. Department of Health and Human Services, Food and Drug Administration, Washington, D.C., 2004.
2. EFPIA: Innovative medicine for Europe. EFPIA, Brussels, 2004.
3. Tufts Center for the Study of Drug Development: Backgrounder: how new drugs move through the development and approval process. Tufts Center, Boston, 2001
4. Gilbert, J., P. Henske, and A. Singh: Rebuilding big pharma's business model. InVivo (The Business & Medicine Report), Windhover Information, 21, No. 10, 2003.
5. Zhang, L., Sinha, V., Forgue, S. T., Callies, S., Ni, L., Peck, R., Allerheiligen, S. R.: Model-based drug development: the road to quantitative pharmacology. J Pharmacokinet Pharmacodyn 2006, 33:369-393.
6. Miller, R., Ewy, W., Corrigan, B. W., Ouellet, D., Hermann, D., Kowalski, K. G., Lockwood, P., Koup J. R, Donevan, S., El-Kattan, A., Li, C. S., Werth, J. L., Feltner, D. E., Lalonde, R. L.: How modeling and simulation have enhanced decision making in new drug development. J Pharmacokinet Pharmacodyn 2005, 32:185-197.
7. Gieschke, R., Steimer, J. L.: Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development. Eur J Drug Metab Pharmacokinet 2000, 25:49-58.
8. Danhof, M., de Jongh, J., De Lange, E. C., Della Pasqua, O., Ploeger, B. A., Voskuyl, R. A.: Mechanism-based pharmacokineticpharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol 2007, 47:357-400.
9. Sheiner, L. B., Steimer, J. L.: Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 2000, 40:67-95.
10. Lockwood, P., Ewy, W., Hermann, D., Holford, N.: Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease. Pharm Res 2006, 23:2050-2059.
11. Holford, N.H. G., Kimko, H. C., Monteleone, J. P. R., Peck, CC.: Simulation of clinical trials. Annu Rev Pharmacol Toxicol 2000, 40:209-234.
12. Sheiner, L. B.: Learning versus confirming in clinical drug development. Clin Pharmacol Ther 1997, 61:275-291.
13. Piotrovsky, V.: Pharmacokinetic and pharmacodynamic variability: estimation and appraisal of its impact on dose optimization with an example of gender differences. In: Krishna, R., ed. Dose optimization in drug development. (Drugs and the pharmaceutical sciences, volume 161) Marcel Dekker, New York, 2006.
14. Piotrovsky, V., Van Peer, A., Van Osselaer, N., Armstrong, M., Aerssens, J.: Galantamine population pharmacokinetics in patients with Alzheimer's disease: modeling and simulations. J Clin Pharmacol 2003, 43:514-523.
15. Sun, H., Fadiran, E. O., Jones, C. D., Lesko, L., Huang, S. M., Higgins, K., Hu, C., Machado, S., Maldonado, S., Williams, R., Hossain, M., Ette, E. I.: Population pharmacokinetics. A regulatory perspective. Clin Pharmacokinet 1999, 37:41-58.
16. Gobburu, J. V., Marroum, P. J.: Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision-making. Clin Pharmacokinet 2001, 40:883-892.
17. Kimko, H. C., Duffull, S. B.: Simulation for designing clinical trials. A pharmacokinetic-pharmacodynamic modeling perspective. (Drugs and the pharmaceutical sciences, volume 127) Marcel Dekker, New York, 2003.
18. Lalonde, R. L., Kowalski, K. G., Hutmacher, M. M., Ewy, W., Nichols, D. J., Milligan, P. A., Corrigan, B. W., Lockwood, P. A., Marshall, S. A., Benincosa, L. J., Tensfeldt, T. G., Parivar, K., Amantea, M., Glue, P., Koide, H., Miller, R.: Modelbased Drug Development. Clin Pharmacol Ther 2007, 82:21-32.
19. Grasela, T. H., Dement, C. W., Kolterman, O. G., Fineman, M. S., Grasela, D. M., Honig, P., Antal, E. J., Bjornsson, T. D., Loh, E.: Pharmacometrics and the transition to model-based development. Clin Pharmacol Ther 2007, 82:137-142.
20. Yano, Y., Beal, S. L., Sheiner, L. B.: Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 2001, 28:171-192.
21. Williams, P. J., Ette, E. I.: Determination of model appropriateness. In: Kimko, H. C., Duffull, S. B., eds. Simulation for designing clinical trials. A pharmacokinetic-pharmacodynamic modeling perspective. (Drugs and the pharmaceutical sciences, volume 127) Marcel Dekker, New York, 2003.
22. Mentre, F., Escolano, S.: Prediction discrepancies for the evaluation of nonlinear mixed-effects models. J Pharmacokinet Pharmacodyn 2006, 33:345-367.
23. Nestorov, I. A.: Sensitivity analysis of pharmacokinetic and pharmacodynamic models in clinical trial simulation and design. In: Kimko, H. C., Duffull, S. B., eds. Simulation for designing clinical trials. A pharmacokinetic-pharmacodynamic modeling perspective. (Drugs and the pharmaceutical sciences, volume 127) Marcel Dekker, New York, 2003.
24. Kraiczi, H., Frisen, M.: Effect of uncertainty about population parameters on pharmacodynamics-based prediction of clinical trial power. Contemp Clin Trials 2005, 26:118-130.
25. Chan, P. L. S., Holford NHG: Drug treatment effects on disease progression. Annu Rev Pharmacol Toxicol 2001, 41:625-659.
26. Piotrovsky, V.: Drug efficacy analysis as an exercise in dynamic (indirectresponse) population PK-PD modelling. Population Approach Group in Europe (PAGE) Meeting, Paris, 2002. Available at: http://www.pagemeeting. org/default.asp?abstract=305.
27. Post, T.M., Freijer, J. I., DeJongh, J., Danhof, M.: Disease system analysis: basic disease progression models in degenerative disease. Pharm Res 2005, 22:1038-1049.
28. Holford, N. H. G.: Input-output models. In: Kimko, H. C., Duffull, S. B., eds. Simulation for designing clinical trials. A pharmacokinetic-pharmacodynamic modeling perspective. (Drugs and the pharmaceutical sciences, volume 127) Marcel Dekker, New York, 2003.
29. Mould, D. R.: Defining covariate distribution models for clinical trial simulation. In: Kimko, H. C., Duffull, S. B., eds. Simulation for designing clinical trials. A pharmacokinetic-pharmacodynamic modeling perspective. (Drugs and the pharmaceutical sciences, volume 127) Marcel Dekker, New York, 2003.
30. Tannenbaum, S. J., Holford, N. H., Lee, H., Peck, C. C., Mould, D. R.: Simulation of correlated continuous and categorical variables using a single multivariate distribution. J Pharmacokinet Pharmacodyn 2006 [Epub ahead of print].
31. Tannenbaum, S. J., Holford, N. H., Lee, H., Peck, C. C., Mould, D. R.: Simulation of correlated continuous and categorical variables using a single multivariate distribution. J Pharmacokinet Pharmacodyn 2006, 33:773-794.
32. Urquhart, J.: Pharmionics: research on what patients do with prescription drugs. Pharmacoepidemiol Drug Saf 2004, 13:587-590.
33. Kastrissios, H., Girard, P.: Protocol deviations and execution models. In: Kimko, H. C., Duffull, S. B., eds. Simulation for designing clinical trials. A pharmacokinetic-pharmacodynamic modeling perspective. (Drugs and the pharmaceutical sciences, volume 127) Marcel Dekker, New York, 2003.
34. Kenna, L. A., Sheiner, L. B.: Estimating treatment effect in the presence of noncompliance measured with error: precision and robustness of data analysis methods. Statist Med 2004, 23:3561-3580.
35. Girard, P.: Clinical trial simulation: a tool for understanding study failures and preventing them. Basic Clin Pharmacol Toxicol 2005, 96:228-234.
36. Olsson Gislekog, P., Jacqmin, P., Perez-Ruixo, J. J.: Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects. Clin Pharmacokin 2006 (in press).
37. Krzyzanski, W., Jusko, W. J., Wacholtz, M. C., Minton, N., Cheung, W. K.: Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur J Pharm Sci 2005, 26:295-306.
38. Jolling, K., Perez-Ruixo, J. J., Hemeryck, A., Vermeulen, A., Greway, T.: Mixedeffects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin. Eur J Pharm Sci 2005, 24:465-475.
39. Woo, S., Jusko, W. J.: Interspecies comparison of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin (rH-EPO). Drug Metabolism and Disposition 2007 (in press).
40. Erickson-Miller, C. L., Pelus, L. M., Lord, K. A.: Signaling induced by erythropoietin and stem cell factor in UT-7/Epo cells: transient versus sustained proliferation. Stem Cells 2000, 18:366-373.
41. Ambrose, P. G. Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the society of infectious diseases pharmacists. Pharmacotherapy 2006, 26:129-134.
42. Drusano, G. L., Preston, S. L., Hardalo, C., Hare, R., Banfield, C., Andes, D., Vesga, O., Craig, W. A.: Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother 2001, 45:13-22.
43. Craig, W. A.: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-10.
44. Preston, S. L., Drusano, G. L., Berman, A. L., Fowler, C. L., Chow, A. T., Dornseif, B., Reichl, V., Natarajan, J., Corrado, M:. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998, 279:125-129.
45. Peck, C. C., Rubin, D. B., Sheiner, L. B.: Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval. Clin Pharmacol Ther 2003, 73:481-490.
46. Lockwood, P. A., Cook, J. A., Ewy, W. E., Mandema, J. W.: The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain. Pharm Res 2003, 20:1752-1759.
47. Mandema, J. W., Hermann, D., Wang, W., Sheiner, T., Milad, M., Bakker-Arkema, R., Hartman, D.: Model-based development of gemcabene, a new lipid-altering agent. AAPS J 2005, 7:E513-E522.
48. Burman, C. F., Hamren, B., Olsson, P.: Modelling and simulation to improve decision-making in clinical development. Pharmaceut Statist 2005, 4:47-58.
49. De Ridder, F.: Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development. Basic Clin Pharmacol Toxicol 2005, 96:235-241.